Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

Published: Thursday, April 24, 2014
Last Updated: Thursday, April 24, 2014
Bookmark and Share
Samsung will manufacture commercial drug substances and drug product at Incheon manufacturing site.

Bristol-Myers Squibb Company and Samsung BioLogics have announced that the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the agreement are not disclosed.

Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.

"Biologic medicines that treat serious diseases are an integral part of Bristol-Myers Squibb’s specialty care portfolio and R&D pipeline,” said Lou Schmukler, president, Global Manufacturing & Supply. “The expanded relationship with Samsung will increase our biologics manufacturing capability and give us the flexibility to respond to increased demand in order to meet the global needs of patients.”

"Samsung is delighted to reach the second manufacturing agreement with Bristol-Myers Squibb and we look forward to delivering top quality GMP production," said Dr. TH Kim, president and CEO of Samsung BioLogics. “It represents another significant step for Samsung and Bristol-Myers Squibb in strengthening our biopharmaceutical manufacturing relationship.”

Samsung brings global biopharmaceutical capability through its fully-integrated production facilities that offer process development, drug substance manufacturing, and drug product fill & finish services at one location.

In addition to its current biologics manufacturing facility in Incheon, Korea, the company is currently building a second facility, also in Incheon, which is expected to be completed in early 2015.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bristol-Myers Squibb and Promedior Enters into Agreement
Agreement providing exclusive right to acquire Promedior, Inc. and its novel PRM-151 in development for fibrotic diseases.
Thursday, September 03, 2015
Bristol-Myers Squibb and uniQure Enter into Strategic Collaboration
Collaboration to develop gene therapies for cardiovascular diseases.
Thursday, April 09, 2015
Bristol-Myers Squibb to Expand its Immuno-Oncology Pipeline
Gains full rights to Flexus’ lead preclinical IDO1 inhibitor F001287 and the company’s broad IDO/TDO discovery program.
Thursday, February 26, 2015
Bristol-Myers Squibb and Calibr Collaborate
Collaboration and license agreement focused on new treatment approaches for fibrotic diseases.
Thursday, January 08, 2015
BMS to Construct a New Large-Scale Biologics Manufacturing Facility in Ireland
Facility will produce multiple therapies for the company’s growing biologics portfolio.
Tuesday, November 25, 2014
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
Contract expansion will include the production of commercial quantities of a second BMS biologic medicine at Lonza’s Portsmouth facility.
Friday, November 07, 2014
Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration
Collaboration to evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in non-Hodgkin lymphoma.
Thursday, October 16, 2014
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement
Phase I study to evaluate OPDIVO (nivolumab), Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, with Celgene’s ABRAXANE® for multiple cancers.
Thursday, August 21, 2014
B-MS, Syngene Extend Research Collaboration
Companies announce a five-year extension of their drug discovery and development collaboration in India.
Wednesday, June 04, 2014
Bristol-Myers Squibb Acquires iPierian
B-MS acquires iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, for $175M.
Thursday, May 01, 2014
U.S. FDA Approves DVT Drug Eliquis®
The approval gives U.S. orthopedic surgeons a new option for DVT prophylaxis in both hip and knee replacement surgery.
Monday, March 17, 2014
Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation
Treatment effects of Eliquis® (apixaban) vs. warfarin, across a broad range of warfarin control, are consistent with primary results of ARISTOTLE.
Tuesday, May 07, 2013
Bristol-Myers Squibb to Acquire Medarex
Bristol-Myers Squibb acquires proven antibody discovery technology gains full rights to promising Phase III compound, Ipilimumab.
Friday, July 24, 2009
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!